A single nucleotide polymorphism in activated cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients

Journal of Hepatology

Volumn 54, Issue 4, 2011, Pages 629-639

  Fujimoto, Yoshifumi ^a,b   Ochi, Hidenori ^a,b   Maekawa, Toshiro ^a   Abe, Hiromi ^a,b   Hayes, C Nelson ^a,b   Kumada, Hiromitsu ^c   Nakamura, Yusuke ^d   Chayama, Kazuaki ^a,b  

^a INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c TORANOMON HOSPITAL   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

ACK1; HCV; Interferon; Tagging SNP

Indexed keywords

ACTIVATED CDC42 ASSOCIATED TYROSINE KINASE; ALPHA INTERFERON; MESSENGER RNA; PEGINTERFERON ALPHA2B; PROTEIN TYROSINE KINASE; RIBAVIRIN; STAT1 PROTEIN; UNCLASSIFIED DRUG;

ACK1 GENE; ADULT; ARTICLE; ASIAN; CANCER CELL CULTURE; CDC42 GENE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RESPONSIVE ELEMENT; DRUG DOSE TITRATION; ETHNICITY; FEMALE; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HAPLOTYPE MAP; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRUS REPLICATION;

ADULT; AGED; ALLELES; CDC42 GTP-BINDING PROTEIN; CELL LINE; FEMALE; GENE FREQUENCY; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-TYROSINE KINASES; RECOMBINANT PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFECTION; TREATMENT OUTCOME;

EID: 79952708654     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.07.021     Document Type: Article

References (38)

1. McHutchison JG. Understanding hepatitis C. Am J Manag Care 2004;10:S21-S29. (Pubitemid 38380782)
2. Global surveillance and control of hepatitis C. Report of a WHO Consultation organization in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35-47.
3. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997;113:558-566. (Pubitemid 27351783)
4. Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, et al. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig 2008;28:9-16. (Pubitemid 350274396)
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
6. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-652. (Pubitemid 37052151)
7. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006;55:529-535.
8. Gao B, Hong F, Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 2004;39:880-890. (Pubitemid 38428923)
9. Hijikata M, Ohta Y, Mishiro S. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/A at nt -88) correlated with the response of hepatitis C patients to interferon. Intervirology 2000;43:124-127.
10. Matsushita M, Hijikata M, Ohta Y, Mishiro S. Association of mannose-binding lectin gene haplotype LXPA and LYPB with interferon-resistant hepatitis C virus infection in Japanese patients. J Hepatol 1998;29:695-700. (Pubitemid 28505924)
11. Sugimoto Y, Kuzushita N, Takehara T, Kanto T, Tatsumi T, Miyagi T, et al. A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influence the interferon response in patients with chronic hepatitis C. J Viral Hepat 2002;9:377-384.
12. Naito M, Matsui A, Inao M. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol 2005;40:381-388. (Pubitemid 40723929)
13. Matsuyama N, Mishiro S, Sugimoto M, Furuichi Y, Hashimoto M, Hijikata M, et al. The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol Res 2003;25:221-225. (Pubitemid 36546347)
14. Tsukada Y, Ochi H, Maekawa T, Abe H, Fujimoto Y, Tsuge M, et al. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis c. Gastroenterology 2009;136:1796-1805.
15. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
16. Helle F, Dubinssion J. Hepatitis C virus entry into host cells. Cell Mol Life Sci 2008;65:100-112. (Pubitemid 351152228)
17. Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003;278:41003-41012.
18. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999;96:12766-12771. (Pubitemid 29513577)
19. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002;21:5017-5025.
20. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998;282:938-941. (Pubitemid 28507525)
21. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007;446:801-805. (Pubitemid 46582027)
22. Brazzoli M, Bianchi A, Filippini S, Weiner A, Zhu Q, Pizza M, et al. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J Virol 2008;82:17.
23. Teo M, Tan L, Lim L, Manser E. The tyrosine kinase ACK1 associates with clathrin-coated vesicles through a binding motif shared by arrestin and other adaptors. J Biol Chem 2001;276:18392-18398.
24. van der Horst EH, Degenhardt YY, Strelow A, Slavin A, Chinn L, Orf J, et al. Metastatic properties and genetic amplification of the tyrosine kinase gene ACK1. Proc Natl Acad Sci USA 2005;102:15901-15906. (Pubitemid 41552840)
25. Galisteo ML, Yang Y, Urena J, Schlessinger J. Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli. Proc Natl Acad Sci USA 2006;103:9796-9801. (Pubitemid 43993577)
26. Kato-Stankiewicz J, Ueda S, Kataoka T, Kaziro Y, Satoh T. Epidermal growth factor stimulation of the ACK1/Dbl pathway in a Cdc42 and Grb2-dependent manner. Biochem Biophys Res Commun 2001;284:470-477. (Pubitemid 32918001)
27. Ozaki K, Ohnishi Y, Iida A, Sekine A, Yamada R, Tsunoda T, et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002;32:650-654. (Pubitemid 35435179)
28. Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003;34:395-402. (Pubitemid 36935332)
29. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y. A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 2002;46:471-477.
30. Iida A, Saito S, Sekine A, Mishima C, Kondo K, Kitamura Y, et al. Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH: ubiquinone oxidoreductase flavoproteins. J Hum Genet 2001;46:668-683. (Pubitemid 33134745)
31. Saito S, Iida A, Sekine A, Miura Y, Sakamoto T, Ogawa C, et al. Identification of 197 genetic variations in six human methyltransferase genes in the Japanese population. J Hum Genet 2001;46:529-537. (Pubitemid 32847568)
32. Hiraga N, Imamura M, Tsuge M, Noguchi C, Takahashi S, Iwao E, et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatic C virus and its susceptibility to interferon. FEBS Lett 2007;581:1983-1987. (Pubitemid 46680431)
33. Devlin B, Risch N. A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 1995;29:311-322.
34. Manser E, Leung T, Salihuddin H, Tan L, Lim L. A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42. Nature 1993;363:364-367. (Pubitemid 23161535)
35. Yokoyama N, Miller WT. Biochemical properties of the Cdc42-associated tyrosine kinase ACK1. J Biol Chem 2003;278:47713-47723.
36. Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol 2001;75:8516-8523. (Pubitemid 32768956)
37. Beadling C, Guschin D, Witthuhn BA, Ziemiecki A, Ihle JN, Kerr IM, et al. Activation of JAK kinases and STAT proteins by interleukin-2 and interferon alpha, but not the T cell antigen receptor, in human T lymphocytes. EMBO J 1994;13:5605-5615. (Pubitemid 24363028)
38. Ahmed I, Calle Y, Sayed MA, Kamal JM, Rengaswamy P, Manser E, et al. Cdc42-dependent nuclear translocation of non-receptor tyrosine kinase, ACK. Biochem Biophys Res Commun 2004;314:571-579. (Pubitemid 38084757)